SCHEMBL3531672

SCHEMBL3531672

CC(C)(C)OC(=O)N1CCCC(=O)c2ccc(Cl)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
BRD4 O60885 1/20 0.43
GPR119 Q8TDV5 2/20 0.40
NOTUM Q6P988 2/20 0.40
ALDH1A1 P00352 2/20 0.39
ESR2 Q92731 1/20 0.38
MPO P05164 1/20 0.38
STS P08842 1/20 0.38
MT-CO2 P00403 1/20 0.38
BUB1 O43683 1/20 0.38
KDM1A O60341 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
AVPR1A P37288 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26405746 0.90 BRD4 (0.46) MEN1KMT2ABRD4GPR119NOTUM
SCHEMBL3531912 0.85 BRD4 (0.43) BRD4GPR119ESR2MPOBUB1
SCHEMBL26916403 0.84 NOTUM (0.44) MEN1KMT2ABRD4GPR119NOTUM
SCHEMBL3532281 0.82 SLC6A15 (0.41) MEN1KMT2ANOTUMALDH1A1HDAC1
SCHEMBL4948953 0.82 NOTUM (0.55) MEN1KMT2ABRD4NOTUMMPO
SCHEMBL14380662 0.82 KDM1A (0.48) MEN1KMT2ABRD4NOTUMALDH1A1
SCHEMBL29960283 0.82 KDM1A (0.48) MEN1KMT2ABRD4NOTUMALDH1A1
SCHEMBL26405750 0.81 BRD4 (0.42) MEN1KMT2ABRD4NOTUMALDH1A1
SCHEMBL22868066 0.80 KDM4E (0.41) KMT2ABRD4GPR119NOTUMESR2
SCHEMBL1815751 0.79 ABHD6 (0.42) MEN1KMT2ABRD4GPR119ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749992-B2 Compounds and methods for treating dislipidemia ELI LILLY AND COMPANY (US) 2010-07-06 US disclosed
EP-1670768-B1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2009-09-09 EP disclosed
EP-2098512-A1 Compounds and methods for treating dyslipidemia Eli Lilly & Company (US) 2009-09-09 EP disclosed
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia ELI LILLY AND COMPANY (US) 2007-11-01 US disclosed
EP-1670768-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-06-21 EP disclosed
WO-2005037796-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254869-A1 Compounds And Methods For Treating Dislipidemia APOB, CETP, PCSK9 MEN1 1183/4885KMT2A 3153/4885BRD4 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.